Verteporfin is being explored for hairregeneration, with unofficial trials and updates shared online. Efforts are being made to encourage more surgeons to trial verteporfin for donor hairregeneration.
Hair loss treatments discussed include promising Pyr available online and Verteporfin dosing after FUE for follicle regeneration, but no updates on SCUBE3.
Dr. Bloxham's trial is testing verteporfin on hair transplant patients to see if it can improve hair regrowth in treated areas. People are discussing the potential for follicle regeneration, expected results timeline, and concerns about side effects like cancer.
Exploring the idea of using facial hair properties for scalp regeneration in male pattern baldness, considering the potential of transferring androgen-resistant characteristics from facial hair to the scalp. Challenges include complexity, scalability, aesthetics, and safety, but the concept encourages innovative thinking beyond current treatments like Minoxidil, Finasteride, and hair transplants.
Bovine colostrum is being discussed for its potential in hairregeneration, with some users noting that oral consumption may not be effective due to stomach acid destroying exosomes. The conversation also touches on ethical concerns about sourcing colostrum.
The conversation discusses verteporfin as a potential treatment for hairregeneration, which could lead to unlimited hair transplants by healing the donor area. Some users are considering using verteporfin now, while others are hopeful it will be available for future hair transplants.
The conversation is about a hair loss treatment routine involving dermarolling, finasteride, minoxidil, and natural oils. Suggestions include using shorter needles for better absorption of treatments and longer needles less frequently for hair follicle regeneration.
The conversation discusses the potential of GT20029 to stop hair loss and possibly regrow hair, considering the body's regenerative abilities. No specific treatments were mentioned due to the original post being removed.
User asks where to purchase exosomes/AAPE for microneedling hair loss treatment. Links to research on hairregeneration therapy, stem cell therapy, exosome therapy, and dermal exosomes provided.
The conversation discusses the use of Verteporfin in hair loss treatment. It suggests that Verteporfin could potentially regeneratehair follicles instead of forming scars, providing an unlimited donor supply for hair transplants.
Verteporfin is discussed as a potential treatment for hair regrowth, but skepticism exists about its effectiveness in regenerating extracted hair follicles. The conversation also mentions the possibility of needing a hair transplant by 2028.
Dr. Kang-Yell Choi's company, CK Regeon, is developing a drug called KY19382 for hairregeneration, which involves creating fine wounds to activate stem cells. The drug is in the formulation development stage, targeting markets like the US and Korea.
User seeks participants for Verteporfin group buy. Verteporfin, FDA approved, may regeneratehair follicles and sweat glands through heavy microneedling.
Exosomes combined with fractional picosecond laser treatment were effective in treating androgenetic alopecia and promoting repigmentation in white hair patches. The role of exosomes in hair repigmentation, particularly in conditions like poliosis, is not well-studied.
Hair follicle stem cells remain in bald individuals, but progenitor cells do not, raising questions about hair regrowth claims by Pelage. PP405 is discussed as a potential treatment, with skepticism about its effectiveness compared to existing treatments like Minoxidil and Finasteride.
Hair cloning and injection of dermal papilla cells are discussed, with skepticism about their availability by 2023. Users mention Minoxidil, finasteride, and hair transplants as current treatments.
Japanese scientists discovered ABM cells, enabling successful human hair follicle cloning, potentially curing hair loss. The treatment may be available in Japan by 2028, but it will be expensive and require travel.
Hair loss research is important and contributes to overall scientific advancement, benefiting emotional well-being and potentially aiding other medical fields. Treatments mentioned include PP405 and SCUBE3.
A new stem cell method for culturing hair follicles is being developed as an alternative to Minoxidil, finasteride, and RU58841. There are concerns about its cost and accessibility despite plans for commercialization.
Hair loss involves more than just DHT, with genetic factors like TRPS affecting hair follicles. Treatments such as Amplifica's AMP-601 and AMP-303 target stem cells for potential hair growth solutions.
A breakthrough in hair follicle cultivation using induced pluripotent stem cells (iPSCs) has been achieved, producing large hair follicles suitable for transplantation. Clinical trials for this hair multiplication technology are planned in partnership with Yinguan Biotechnology.
The conversation discusses the complexity of hair loss causes, suggesting that DHT sensitivity alone doesn't fully explain it. Treatments mentioned include finasteride and dutasteride.
Hair loss treatments are being tested on mice, with methods like minoxidil and stem cell therapy showing promising results. However, human trials are still years away, leading to humorous frustration about mice benefiting first.
Hair loss impacts mental health, with treatments like Minoxidil, finasteride, and stem cell transplants discussed. There is hope for future breakthroughs, but current treatments are limited, and awareness is lacking.
Hair cloning is seen as a distant and potentially less relevant solution for hair loss due to its high cost, invasiveness, and the advancement of other treatments like Minoxidil and finasteride. Many believe that by the time hair cloning becomes viable, other less invasive and more effective treatments will be available.
Hair loss is influenced by genetics and sensitivity to hormones like DHT. Treatments like Minoxidil and finasteride are commonly used, and baldness persists as it doesn't affect reproductive success.
Hair follicles can be dormant and potentially revived with treatments like finasteride and minoxidil, but irreversible loss occurs if certain structures are destroyed. Early intervention is more effective, and additional methods like microneedling may help.
OP shared a 7-year hair density progress update using Minoxidil, Finasteride, and dermarolling. Creatine use was discussed, with mixed opinions on its impact on hair loss.
AMP-303 and AMP-601 are new hair loss treatments targeting dermal papilla cells, with AMP-303 showing early efficacy in transitioning vellus hairs to terminal hairs after one injection. Further clinical trials are planned, and these treatments are seen as promising due to their biologic approach and less frequent application compared to daily treatments.